Harmony Biosciences Holdings Inc (HRMY)
ROE
Obliczenia
|
2023/Q4 (31 gru 2023) |
2023/Q3 (30 wrz 2023) |
2023/Q2 (30 cze 2023) |
2023/Q1 (31 mar 2023) |
2022/Q4 (31 gru 2022) |
2022/Q3 (30 wrz 2022) |
2022/Q2 (30 cze 2022) |
2022/Q1 (31 mar 2022) |
||
|---|---|---|---|---|---|---|---|---|---|
| Zysk netto (ttm) | w tys. USD | 128 853 | 150 755 | 200 237 | 189 468 | 181 468 | 155 673 | 58 110 | 48 696 |
| Kapitał własny | w tys. USD | 466 992 | 481 332 | 485 172 | 443 041 | 402 838 | 343 884 | 246 533 | 214 503 |
| ROE | 27,59% | 31,32% | 41,27% | 42,77% | 45,05% | 45,27% | 23,57% | 22,70% |
2023/Q4 obliczenia
ROE = Zysk netto (ttm) ÷ Kapitał własny
= $128 853K ÷ $466 992K
= 27,59%
Analiza porównawcza
2023/Q4
Nazwa spółki
Symbol
ROE
Harmony Biosciences Holdings Inc
HRMY
27,59%
Amphastar Pharmaceuticals Inc
AMPH
21,51%
Arcus Biosciences Inc
RCUS
-66,45%
Catalyst Pharmaceuticals Inc
CPRX
18,41%
Corcept Therapeutics Inc
CORT
20,95%
Dynavax Technologies Corp.
DVAX
-1,03%
Ironwood Pharmaceuticals Inc
IRWD
—
Myriad Genetics, Inc.
MYGN
-33,62%
Pacira BioSciences Inc
PCRX
4,82%
Supernus Pharmaceuticals Inc
SUPN
0,14%
Xencor Inc
XNCR
-18,85%